The Attention Deficit Hyperactivity Disorder (ADHD) drugs in development market research report provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Attention Deficit Hyperactivity Disorder (ADHD). Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued products.

GlobalData tracks 68 drugs in development for Attention Deficit Hyperactivity Disorder (ADHD) by 54 companies/universities/institutes. The top development phase for Attention Deficit Hyperactivity Disorder (ADHD) is preclinical with 33 drugs in that stage. The Attention Deficit Hyperactivity Disorder (ADHD) pipeline has 65 drugs in development by companies and three by universities/ institutes. Some of the companies in the Attention Deficit Hyperactivity Disorder (ADHD) pipeline products market are: 3Z ehf, Pediatrix Therapeutics and Tris Pharma.

The key targets in the Attention Deficit Hyperactivity Disorder (ADHD) pipeline products market include Sodium Dependent Noradrenaline Transporter (Norepinephrine Transporter or NET or Solute Carrier Family 6 Member 2 or SLC6A2), Sodium Dependent Dopamine Transporter (DA Transporter or DAT or Solute Carrier Family 6 Member 3 or SLC6A3), and Sodium Dependent Serotonin Transporter (5HT Transporter or 5HTT or Solute Carrier Family 6 Member 4 or SLC6A4).

The key mechanisms of action in the Attention Deficit Hyperactivity Disorder (ADHD) pipeline product include Sodium Dependent Noradrenaline Transporter (Norepinephrine Transporter or NET or Solute Carrier Family 6 Member 2 or SLC6A2) Inhibitor with 22 drugs in Pre-Registration. The Attention Deficit Hyperactivity Disorder (ADHD) pipeline products include six routes of administration with the top ROA being Oral and two key molecule types in the Attention Deficit Hyperactivity Disorder (ADHD) pipeline products market including Small Molecule, and Enzyme.

Attention Deficit Hyperactivity Disorder (ADHD) overview

Attention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity, and impulsiveness. Symptoms of ADHD include disorganized work habits, procrastination, and inability to sustain attention on tasks or activities. Treatment includes analeptics.

For a complete picture of Attention Deficit Hyperactivity Disorder (ADHD)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.